BeOne Medicines Ltd. (ONC)
416.54
+0.58
(+0.14%)
USD |
NASDAQ |
Nov 13, 16:00
416.76
+0.22
(+0.05%)
After-Hours: 19:59
BeOne Medicines Enterprise Value : 40.06B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 40.06B |
| November 12, 2026 | 40.00B |
| November 11, 2026 | 40.42B |
| November 10, 2026 | 40.84B |
| November 09, 2026 | 40.14B |
| November 06, 2026 | 39.05B |
| November 05, 2026 | 36.98B |
| November 04, 2026 | 35.98B |
| November 03, 2026 | 33.58B |
| November 02, 2026 | 34.24B |
| October 30, 2026 | 35.19B |
| October 29, 2026 | 35.32B |
| October 28, 2026 | 35.51B |
| October 27, 2026 | 34.74B |
| October 26, 2026 | 35.25B |
| October 23, 2026 | 35.96B |
| October 22, 2026 | 36.45B |
| October 21, 2026 | 36.89B |
| October 20, 2026 | 36.69B |
| October 19, 2026 | 35.18B |
| October 16, 2026 | 35.06B |
| October 15, 2026 | 35.59B |
| October 14, 2026 | 33.21B |
| October 13, 2026 | 32.96B |
| October 12, 2026 | 33.10B |
| Date | Value |
|---|---|
| October 09, 2026 | 33.53B |
| October 08, 2026 | 33.07B |
| October 07, 2026 | 34.53B |
| October 06, 2026 | 34.40B |
| October 05, 2026 | 34.28B |
| October 02, 2026 | 33.90B |
| October 01, 2026 | 33.98B |
| September 30, 2026 | 34.73B |
| September 29, 2026 | 34.84B |
| September 28, 2026 | 35.02B |
| September 25, 2026 | 34.38B |
| September 24, 2026 | 34.29B |
| September 23, 2026 | 34.81B |
| September 22, 2026 | 35.13B |
| September 21, 2026 | 34.88B |
| September 18, 2026 | 33.34B |
| September 17, 2026 | 33.61B |
| September 16, 2026 | 33.05B |
| September 15, 2026 | 32.89B |
| September 14, 2026 | 33.65B |
| September 11, 2026 | 32.89B |
| September 10, 2026 | 32.40B |
| September 09, 2026 | 33.35B |
| September 08, 2026 | 33.40B |
| September 04, 2026 | 34.11B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| AC Immune SA | 110.19M |
| CRISPR Therapeutics AG | 2.598B |
| Idorsia Ltd. | 2.788B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 385.73M |
| Revenue (Quarterly) | 1.895B |
| Total Expenses (Quarterly) | 1.509B |
| EPS Diluted (Quarterly) | 3.288 |
| Gross Profit Margin (Quarterly) | 86.84% |
| Profit Margin (Quarterly) | 20.36% |
| Earnings Yield | 1.89% |
| Operating Earnings Yield | 2.44% |
| Normalized Earnings Yield | 1.945 |